# A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

> **NCT06089616** · — · RECRUITING · sponsor: **Ipsen** · enrollment: 100 (estimated)

## Conditions studied

- Fibrodysplasia Ossificans Progressiva

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06089616
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-05
- **Primary completion:** 2035-12-05
- **Final completion:** 2035-12-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06089616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06089616, "A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06089616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*